

In-Silico Studies, Synthesis, Characterization, Biological Evaluation Of Few Novel Schiff Bases Of Coumarin Derivatives.

MD Ameer¹, Rakesh Panda², Dr. Kalpana Devi³, Dr Md Salahuddin⁴, Ayesha Nida⁵.

¹PG Student, Department of Pharmaceutical Chemistry, Al-Ameen College of Pharmacy, Bengaluru
Karnataka-560027.

ABSTRACT

A series of coumarin derivatives were synthesized and characterized using IR, ¹H NMR, ¹³C NMR, and mass spectrometry. The synthesis involved three steps: condensation of resorcinol with ethyl acetoacetate to yield 7-hydroxy-3-methyl coumarin, confirmed by an IR band at 3489.41 cm⁻¹; Pechmann condensation with substituted benzaldehydes forming coumarin derivatives, indicated by IR peaks at 1642 cm⁻¹ (C=C), 1207 cm⁻¹ (C–O), and 1736 cm⁻¹ (C=O); and Schiff base formation with primary amines producing MARP-1 to MARP-10, confirmed by C=N stretching at 1600–1700 cm⁻¹.

In-silico studies showed that MARP-3 (Cl), MARP-9 (NO₂), and MARP-10 (2,2-diphenyl) had strong binding affinities toward PDB ID: 8THH, correlating with notable anticonvulsant, antioxidant, and anti-inflammatory activities. MARP-3 and MARP-10 exhibited the best anticonvulsant effects, while MARP-8 showed 90% antioxidant inhibition in the DPPH assay. MARP-2 and MARP-8 displayed strong anti-inflammatory activity, preventing 89.15% and 85.41% of BSA protein denaturation, respectively.

Antimicrobial studies revealed MARP-4, MARP-8, and MARP-10 were active against *Staphylococcus aureus* and *Escherichia coli*, with MARP-10 showing the largest inhibition zone. ProTox-II predictions classified most compounds as Class IV, suggesting good safety profiles with no major toxic effects. All compounds followed Lipinski's rule of five, and SwissADME results confirmed favorable absorption and pharmacokinetic profiles.

Overall, the synthesized coumarin derivatives demonstrate significant therapeutic potential supported by both experimental and computational studies.

1. Introduction

Coumarin is a naturally occurring oxygen-containing heterocyclic compound composed of benzene and α -pyrone rings. According to IUPAC nomenclature, it is named 2H-1-benzopyran-2-one and belongs to the lactone class. Coumarins are classified into pyranocoumarins, furanocoumarins, and pyrone-substituted derivatives.

Coumarins, also known as benzopyran-2-ones or chromen-2-ones, are widely distributed in plants, fungi, and bacteria and can be easily modified to yield various biologically active compounds. N-substituted 4-aminocoumarins and their derivatives have gained significant interest due to their promising biological properties. The coumarin framework remains important for its occurrence in natural products, pharmacological activities, and photophysical characteristics.

Numerous natural and synthetic coumarins exhibit antimicrobial, antifungal, cytotoxic, antitumor, anticoagulant, and anti-inflammatory effects. Some natural derivatives, such as novobiocin, warfarin, acenocoumarin, and umbelliferone, are already used clinically. 3-Aminocoumarin derivatives also show diverse actions like CNS depressant, antibacterial, and antiallergic effects. Because of their nucleophilic

and electrophilic behavior, coumarins participate in various reactions, making them versatile building blocks in organic and medicinal chemistry.

Schiff Base Synthesis

Schiff bases are compounds containing the imine ($-C=N-$) group, first reported by Hugo Schiff in 1864. They are synthesized by the condensation of primary amines or hydrazides with carbonyl compounds, releasing water. Structurally, Schiff bases are nitrogen analogs of carbonyl compounds where $C=O$ is replaced by $C=N$.


They serve as important intermediates in organic synthesis and exhibit broad biological activities, including anti-inflammatory, antimicrobial, anticancer, and antioxidant properties, making them valuable precursors for pharmacologically active molecules.

2. OBJECTIVES


- 1) Synthesis of some novel coumarin derivatives.
- 2) Characterization of newly synthesized derivatives using spectral studies.
- 3) Drug likeliness property of the derivatives by using Swiss ADME and Molinspiration web servers.
- 4) Online toxicity prediction.
- 5) Molecular Docking studies by using Autodock software
- 6) *In vitro* evaluation of the derivatives for their anti-inflammatory and antimicrobial, antioxidant.
- 7) *In vivo* evaluation of the derivatives for their anti convulsant activity.

Review of Literature


Z M Nofal and co-workers synthesized a number of novel 3-bromo-4-methyl-7-methoxy-8-amino substituted coumarins and 2-substituted 7-bromo-6-methyl-8H-pyrano-benzimidazoles, benzoxazoles and/or benzoxazine-8-ones for the purpose of pharmacological evaluation. The representative compounds showed antitumor activity *in-vitro* on Ehrlich ascites carcinoma in the preliminary testing.




Chandarajoti K and coworkers designed new coumarin derivatives using a 2-(2-oxo-2H-chromen-4-yl)acetic acid scaffold conjugated with amino acid esters or tyramine. The anti-tyrosinase and anti-lipid peroxidation activities of the synthesized compounds were investigated. Coumarin derivatives showed strong anti-lipid peroxidation activity. The structures of the synthesized compounds were confirmed by infrared spectroscopy, 1H and ^{13}C nuclear magnetic resonance spectroscopy. Few of reported compounds offer potential for development as skin-lightening agents and vitiligo therapy agents, respectively.




Zhou R and co-workers synthesized new coumarin derivatives and evaluated their biological activities. Their structures were confirmed by NMR data. Ten of the synthesized compounds were investigated for antimetastatic activity against lung carcinoma cells.




Kowalczyk P and coworkers synthesized a library of novel peptidomimetics via Ugi multicomponent reaction. Most of these peptidomimetics contain differently substituted aminocoumarin 7-amino-4-methylcoumarin and 7-amino-4-(trifluoromethyl) coumarin. ^1H - and ^{13}C NMR spectra were recorded in Chloroform-d at Bruker 400 and Varian 500 MHz spectrometer using TMS. Preliminary cellular studies suggested that the compounds with coumarin derivatives had more potential as antimicrobial agents compared to the compounds without coumarin.




Khunnawutmanotham N and co-workers synthesized a series of 3-amino-6,7-dimethoxycoumarins conjugated with the N-benzylpyridinium moiety through an amide-bond linkage and evaluated for their acetylcholinesterase inhibitory activity. Docking studies revealed that the synthesized compounds inhibit the target enzyme by a dual binding site mechanism.



Xu L and co workers designed and synthesized 4-amino coumarin-based derivatives. The structures had been confirmed by MS, ^1H NMR and ^{13}C NMR. Most of the compounds expressed broad-spectrum antifungal activity against four plant pathogenic fungi using the mycelium growth inhibition method. The present work indicated that these derivatives would serve as novel potential fungicides targeting SDH



Novica Ristic and coworkers reported the synthesis, spectral characterization, and evaluation of *in vitro* antioxidant activity of a new coumarin derivative, 4-((1,3,4-thiadiazol-2-yl)amino)-3-nitro-2H-chromene-2-one. The synthesis of the new product was performed in three reaction steps, with a good overall yield (78%). The structure was corroborated by detailed spectral analysis, including the 1D and 2D NMR experiments. *In vitro* antioxidant activity was evaluated using the DPPH test. The synthesized compound possessed a good free-radical scavenging activity and could serve as a model for the synthesis with promising antioxidant effects.



4.METHODOY

SYNTHETIC SCHEME:





Table 1: List of the 4-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)benzaldehyde (MARP 1-10)
(MARP 1-10 derivatives).

Procedure for the synthesis of novel coumarin :

STEP-1: 1.11gm of resorcinol (0.01mol) was added to 1.27ml (0.01mol) of distilled ethyl-acetoacetate and kept in an ice bath. 10ml of H₂SO₄ was added drop wise to the mixture and stirred continuously in a magnetic stirrer. The completion of the reaction was confirmed by TLC using n-hexane and ethyl acetate (3:2). The reaction mixture was poured slowly into ice-cold water with stirring. The precipitate obtained was filtered washed with cold water and recrystallized with 65% ethanol.

STEP-2: To a solution of compound (2) (2.34g, 0.01 mol) in (30 ml) Ethanol, appropriate aromatic aldehyde (4-Bromo benzaldehyde 2- Bromo benzaldehyde, 2- Chlorobenzaldehyde and 4-Chloro benzaldehyde) (0.02 mol) was added in the presence of (4-5) drops of Piperidine with continuous stirring for 30 min. the mixture was refluxed for 8 hours, then the reaction mixture was cooled, The product was filtered and recrystallized from Ethanol solvent.


STEP-3: To a solution of (0.01 mole) compound (2) in (25 ml) absolute ethanol, an appropriate aromatic amine, (0.01 mole) of aniline and (0.005 mole) of 4-amino benzoic acid and 4-nitro aniline), was added

with continuous stirring, and then was refluxed for a period of 30 min, the precipitate formed was filtered, dried and recrystallized from ethanol.

MARP-3: 6(4(((2chlorophenyl)imino)methyl)phenoxy)-4-methyl-2H-chromen-2-one

Compound code: MARP-3

Structure:



IUPAC Name: 6-(4-(((2-chlorophenyl)imino)methyl)phenoxy)-4-methyl-2H-chromen-2-one

Physical Properties-

Mol formula & weight: C₂₃H₁₆ClNO₃ and 389.83,

Colour: Off Pink,

Melting Rang: 111-115^oC,

Rf Value: 0.80,


Solubility: Methanol, DMSO,

%Yield : 56%


IR cm⁻¹:

3110.9(CH₃ str), 1666.6(C=N str), 1488(Ar C=C), 1593.6(C=O), 1273(C-O), 748(C-Cl).

¹HNMR:




MARP-3-DMSO-PROTON




```

Current Data Parameters
NAME: 24092025
EXPNO: 1
PROCNO: 1
F2 - Acquisition Parameters
Date_ : 20250926
Time: 19:09
INSTRUM: spect
PROBHD: zgpg30
PULPROG: zgpg30
PCPDPRG:
SOLVENT: DMSO
NS: 16
DS: 4
AQ: 0.18120000
RG: 327.50
FIDRES: 0.142412
AQRES: 4.084445
NUC1: 13C
NUC2: 13C
NUC3:
NUC4:
NUC5:
NUC6:
SFO: 100.626126
SFO2: 100.626126
SFO3: 100.626126
SFO4: 100.626126
SFO5: 100.626126
SFO6: 100.626126
SFO7: 100.626126
SFO8: 100.626126
SFO9: 100.626126
SFO10: 100.626126
SFO11: 100.626126
SFO12: 100.626126
SFO13: 100.626126
SFO14: 100.626126
SFO15: 100.626126
SFO16: 100.626126
SFO17: 100.626126
SFO18: 100.626126
SFO19: 100.626126
SFO20: 100.626126
SFO21: 100.626126
SFO22: 100.626126
SFO23: 100.626126
SFO24: 100.626126
SFO25: 100.626126
SFO26: 100.626126
SFO27: 100.626126
SFO28: 100.626126
SFO29: 100.626126
SFO30: 100.626126
SFO31: 100.626126
SFO32: 100.626126
SFO33: 100.626126
SFO34: 100.626126
SFO35: 100.626126
SFO36: 100.626126
SFO37: 100.626126
SFO38: 100.626126
SFO39: 100.626126
SFO40: 100.626126
SFO41: 100.626126
SFO42: 100.626126
SFO43: 100.626126
SFO44: 100.626126
SFO45: 100.626126
SFO46: 100.626126
SFO47: 100.626126
SFO48: 100.626126
SFO49: 100.626126
SFO50: 100.626126
SFO51: 100.626126
SFO52: 100.626126
SFO53: 100.626126
SFO54: 100.626126
SFO55: 100.626126
SFO56: 100.626126
SFO57: 100.626126
SFO58: 100.626126
SFO59: 100.626126
SFO60: 100.626126
SFO61: 100.626126
SFO62: 100.626126
SFO63: 100.626126
SFO64: 100.626126
SFO65: 100.626126
SFO66: 100.626126
SFO67: 100.626126
SFO68: 100.626126
SFO69: 100.626126
SFO70: 100.626126
SFO71: 100.626126
SFO72: 100.626126
SFO73: 100.626126
SFO74: 100.626126
SFO75: 100.626126
SFO76: 100.626126
SFO77: 100.626126
SFO78: 100.626126
SFO79: 100.626126
SFO80: 100.626126
SFO81: 100.626126
SFO82: 100.626126
SFO83: 100.626126
SFO84: 100.626126
SFO85: 100.626126
SFO86: 100.626126
SFO87: 100.626126
SFO88: 100.626126
SFO89: 100.626126
SFO90: 100.626126
SFO91: 100.626126
SFO92: 100.626126
SFO93: 100.626126
SFO94: 100.626126
SFO95: 100.626126
SFO96: 100.626126
SFO97: 100.626126
SFO98: 100.626126
SFO99: 100.626126
SFO100: 100.626126
SFO101: 100.626126
SFO102: 100.626126
SFO103: 100.626126
SFO104: 100.626126
SFO105: 100.626126
SFO106: 100.626126
SFO107: 100.626126
SFO108: 100.626126
SFO109: 100.626126
SFO110: 100.626126
SFO111: 100.626126
SFO112: 100.626126
SFO113: 100.626126
SFO114: 100.626126
SFO115: 100.626126
SFO116: 100.626126
SFO117: 100.626126
SFO118: 100.626126
SFO119: 100.626126
SFO120: 100.626126
SFO121: 100.626126
SFO122: 100.626126
SFO123: 100.626126
SFO124: 100.626126
SFO125: 100.626126
SFO126: 100.626126
SFO127: 100.626126
SFO128: 100.626126
SFO129: 100.626126
SFO130: 100.626126
SFO131: 100.626126
SFO132: 100.626126
SFO133: 100.626126
SFO134: 100.626126
SFO135: 100.626126
SFO136: 100.626126
SFO137: 100.626126
SFO138: 100.626126
SFO139: 100.626126
SFO140: 100.626126
SFO141: 100.626126
SFO142: 100.626126
SFO143: 100.626126
SFO144: 100.626126
SFO145: 100.626126
SFO146: 100.626126
SFO147: 100.626126
SFO148: 100.626126
SFO149: 100.626126
SFO150: 100.626126
SFO151: 100.626126
SFO152: 100.626126
SFO153: 100.626126
SFO154: 100.626126
SFO155: 100.626126
SFO156: 100.626126
SFO157: 100.626126
SFO158: 100.626126
SFO159: 100.626126
SFO160: 100.626126
SFO161: 100.626126
SFO162: 100.626126
SFO163: 100.626126
SFO164: 100.626126
SFO165: 100.626126
SFO166: 100.626126
SFO167: 100.626126
SFO168: 100.626126
SFO169: 100.626126
SFO170: 100.626126
SFO171: 100.626126
SFO172: 100.626126
SFO173: 100.626126
SFO174: 100.626126
SFO175: 100.626126
SFO176: 100.626126
SFO177: 100.626126
SFO178: 100.626126
SFO179: 100.626126
SFO180: 100.626126
SFO181: 100.626126
SFO182: 100.626126
SFO183: 100.626126
SFO184: 100.626126
SFO185: 100.626126
SFO186: 100.626126
SFO187: 100.626126
SFO188: 100.626126
SFO189: 100.626126
SFO190: 100.626126
SFO191: 100.626126
SFO192: 100.626126
SFO193: 100.626126
SFO194: 100.626126
SFO195: 100.626126
SFO196: 100.626126
SFO197: 100.626126
SFO198: 100.626126
SFO199: 100.626126
SFO200: 100.626126
SFO201: 100.626126
SFO202: 100.626126
SFO203: 100.626126
SFO204: 100.626126
SFO205: 100.626126
SFO206: 100.626126
SFO207: 100.626126
SFO208: 100.626126
SFO209: 100.626126
SFO210: 100.626126
SFO211: 100.626126
SFO212: 100.626126
SFO213: 100.626126
SFO214: 100.626126
SFO215: 100.626126
SFO216: 100.626126
SFO217: 100.626126
SFO218: 100.626126
SFO219: 100.626126
SFO220: 100.626126
SFO221: 100.626126
SFO222: 100.626126
SFO223: 100.626126
SFO224: 100.626126
SFO225: 100.626126
SFO226: 100.626126
SFO227: 100.626126
SFO228: 100.626126
SFO229: 100.626126
SFO230: 100.626126
SFO231: 100.626126
SFO232: 100.626126
SFO233: 100.626126
SFO234: 100.626126
SFO235: 100.626126
SFO236: 100.626126
SFO237: 100.626126
SFO238: 100.626126
SFO239: 100.626126
SFO240: 100.626126
SFO241: 100.626126
SFO242: 100.626126
SFO243: 100.626126
SFO244: 100.626126
SFO245: 100.626126
SFO246: 100.626126
SFO247: 100.626126
SFO248: 100.626126
SFO249: 100.626126
SFO250: 100.626126
SFO251: 100.626126
SFO252: 100.626126
SFO253: 100.626126
SFO254: 100.626126
SFO255: 100.626126
SFO256: 100.626126
SFO257: 100.626126
SFO258: 100.626126
SFO259: 100.626126
SFO260: 100.626126
SFO261: 100.626126
SFO262: 100.626126
SFO263: 100.626126
SFO264: 100.626126
SFO265: 100.626126
SFO266: 100.626126
SFO267: 100.626126
SFO268: 100.626126
SFO269: 100.626126
SFO270: 100.626126
SFO271: 100.626126
SFO272: 100.626126
SFO273: 100.626126
SFO274: 100.626126
SFO275: 100.626126
SFO276: 100.626126
SFO277: 100.626126
SFO278: 100.626126
SFO279: 100.626126
SFO280: 100.626126
SFO281: 100.626126
SFO282: 100.626126
SFO283: 100.626126
SFO284: 100.626126
SFO285: 100.626126
SFO286: 100.626126
SFO287: 100.626126
SFO288: 100.626126
SFO289: 100.626126
SFO290: 100.626126
SFO291: 100.626126
SFO292: 100.626126
SFO293: 100.626126
SFO294: 100.626126
SFO295: 100.626126
SFO296: 100.626126
SFO297: 100.626126
SFO298: 100.626126
SFO299: 100.626126
SFO300: 100.626126
SFO301: 100.626126
SFO302: 100.626126
SFO303: 100.626126
SFO304: 100.626126
SFO305: 100.626126
SFO306: 100.626126
SFO307: 100.626126
SFO308: 100.626126
SFO309: 100.626126
SFO310: 100.626126
SFO311: 100.626126
SFO312: 100.626126
SFO313: 100.626126
SFO314: 100.626126
SFO315: 100.626126
SFO316: 100.626126
SFO317: 100.626126
SFO318: 100.626126
SFO319: 100.626126
SFO320: 100.626126
SFO321: 100.626126
SFO322: 100.626126
SFO323: 100.626126
SFO324: 100.626126
SFO325: 100.626126
SFO326: 100.626126
SFO327: 100.626126
SFO328: 100.626126
SFO329: 100.626126
SFO330: 100.626126
SFO331: 100.626126
SFO332: 100.626126
SFO333: 100.626126
SFO334: 100.626126
SFO335: 100.626126
SFO336: 100.626126
SFO337: 100.626126
SFO338: 100.626126
SFO339: 100.626126
SFO340: 100.626126
SFO341: 100.626126
SFO342: 100.626126
SFO343: 100.626126
SFO344: 100.626126
SFO345: 100.626126
SFO346: 100.626126
SFO347: 100.626126
SFO348: 100.626126
SFO349: 100.626126
SFO350: 100.626126
SFO351: 100.626126
SFO352: 100.626126
SFO353: 100.626126
SFO354: 100.626126
SFO355: 100.626126
SFO356: 100.626126
SFO357: 100.626126
SFO358: 100.626126
SFO359: 100.626126
SFO360: 100.626126
SFO361: 100.626126
SFO362: 100.626126
SFO363: 100.626126
SFO364: 100.626126
SFO365: 100.626126
SFO366: 100.626126
SFO367: 100.626126
SFO368: 100.626126
SFO369: 100.626126
SFO370: 100.626126
SFO371: 100.626126
SFO372: 100.626126
SFO373: 100.626126
SFO374: 100.626126
SFO375: 100.626126
SFO376: 100.626126
SFO377: 100.626126
SFO378: 100.626126
SFO379: 100.626126
SFO380: 100.626126
SFO381: 100.626126
SFO382: 100.626126
SFO383: 100.626126
SFO384: 100.626126
SFO385: 100.626126
SFO386: 100.626126
SFO387: 100.626126
SFO388: 100.626126
SFO389: 100.626126
SFO390: 100.626126
SFO391: 100.626126
SFO392: 100.626126
SFO393: 100.626126
SFO394: 100.626126
SFO395: 100.626126
SFO396: 100.626126
SFO397: 100.626126
SFO398: 100.626126
SFO399: 100.626126
SFO400: 100.626126
SFO401: 100.626126
SFO402: 100.626126
SFO403: 100.626126
SFO404: 100.626126
SFO405: 100.626126
SFO406: 100.626126
SFO407: 100.626126
SFO408: 100.626126
SFO409: 100.626126
SFO410: 100.626126
SFO411: 100.626126
SFO412: 100.626126
SFO413: 100.626126
SFO414: 100.626126
SFO415: 100.626126
SFO416: 100.626126
SFO417: 100.626126
SFO418: 100.626126
SFO419: 100.626126
SFO420: 100.626126
SFO421: 100.626126
SFO422: 100.626126
SFO423: 100.626126
SFO424: 100.626126
SFO425: 100.626126
SFO426: 100.626126
SFO427: 100.626126
SFO428: 100.626126
SFO429: 100.626126
SFO430: 100.626126
SFO431: 100.626126
SFO432: 100.626126
SFO433: 100.626126
SFO434: 100.626126
SFO435: 100.626126
SFO436: 100.626126
SFO437: 100.626126
SFO438: 100.626126
SFO439: 100.626126
SFO440: 100.626126
SFO441: 100.626126
SFO442: 100.626126
SFO443: 100.626126
SFO444: 100.626126
SFO445: 100.626126
SFO446: 100.626126
SFO447: 100.626126
SFO448: 100.626126
SFO449: 100.626126
SFO450: 100.626126
SFO451: 100.626126
SFO452: 100.626126
SFO453: 100.626126
SFO454: 100.626126
SFO455: 100.626126
SFO456: 100.626126
SFO457: 100.626126
SFO458: 100.626126
SFO459: 100.626126
SFO460: 100.626126
SFO461: 100.626126
SFO462: 100.626126
SFO463: 100.626126
SFO464: 100.626126
SFO465: 100.626126
SFO466: 100.626126
SFO467: 100.626126
SFO468: 100.626126
SFO469: 100.626126
SFO470: 100.626126
SFO471: 100.626126
SFO472: 100.626126
SFO473: 100.626126
SFO474: 100.626126
SFO475: 100.626126
SFO476: 100.626126
SFO477: 100.626126
SFO478: 100.626126
SFO479: 100.626126
SFO480: 100.626126
SFO481: 100.626126
SFO482: 100.626126
SFO483: 100.626126
SFO484: 100.626126
SFO485: 100.626126
SFO486: 100.626126
SFO487: 100.626126
SFO488: 100.626126
SFO489: 100.626126
SFO490: 100.626126
SFO491: 100.626126
SFO492: 100.626126
SFO493: 100.626126
SFO494: 100.626126
SFO495: 100.626126
SFO496: 100.626126
SFO497: 100.626126
SFO498: 100.626126
SFO499: 100.626126
SFO500: 100.626126
SFO501: 100.626126
SFO502: 100.626126
SFO503: 100.626126
SFO504: 100.626126
SFO505: 100.626126
SFO506: 100.626126
SFO507: 100.626126
SFO508: 100.626126
SFO509: 100.626126
SFO510: 100.626126
SFO511: 100.626126
SFO512: 100.626126
SFO513: 100.626126
SFO514: 100.626126
SFO515: 100.626126
SFO516: 100.626126
SFO517: 100.626126
SFO518: 100.626126
SFO519: 100.626126
SFO520: 100.626126
SFO521: 100.626126
SFO522: 100.626126
SFO523: 100.626126
SFO524: 100.626126
SFO525: 100.626126
SFO526: 100.626126
SFO527: 100.626126
SFO528: 100.626126
SFO529: 100.626126
SFO530: 100.626126
SFO531: 100.626126
SFO532: 100.626126
SFO533: 100.626126
SFO534: 100.626126
SFO535: 100.626126
SFO536: 100.626126
SFO537: 100.626126
SFO538: 100.626126
SFO539: 100.626126
SFO540: 100.626126
SFO541: 100.626126
SFO542: 100.626126
SFO543: 100.626126
SFO544: 100.626126
SFO545: 100.626126
SFO546: 100.626126
SFO547: 100.626126
SFO548: 100.626126
SFO549: 100.626126
SFO550: 100.626126
SFO551: 100.626126
SFO552: 100.626126
SFO553: 100.626126
SFO554: 100.626126
SFO555: 100.626126
SFO556: 100.626126
SFO557: 100.626126
SFO558: 100.626126
SFO559: 100.626126
SFO560: 100.626126
SFO561: 100.626126
SFO562: 100.626126
SFO563: 100.626126
SFO564: 100.626126
SFO565: 100.626126
SFO566: 100.626126
SFO567: 100.626126
SFO568: 100.626126
SFO569: 100.626126
SFO570: 100.626126
SFO571: 100.626126
SFO572: 100.626126
SFO573: 100.626126
SFO574: 100.626126
SFO575: 100.626126
SFO576: 100.626126
SFO577: 100.626126
SFO578: 100.626126
SFO579: 100.626126
SFO580: 100.626126
SFO581: 100.626126
SFO582: 100.626126
SFO583: 100.626126
SFO584: 100.626126
SFO585: 100.626126
SFO586: 100.626126
SFO587: 100.626126
SFO588: 100.626126
SFO589: 100.626126
SFO590: 100.626126
SFO591: 100.626126
SFO592: 100.626126
SFO593: 100.626126
SFO594: 100.626126
SFO595: 100.626126
SFO596: 100.626126
SFO597: 100.626126
SFO598: 100.626126
SFO599: 100.626126
SFO600: 100.626126
SFO601: 100.626126
SFO602: 100.626126
SFO603: 100
```

¹³CNMR:




MARP-3 -DMSO-CARBON



δ : (C1=161.58), (C23=18.47), (C16=160.74), (C12 C10 =129.37), (C3=148.87)

MASS:




(m/z)=391.48[M⁺]

Research Through Innovation

DOCKING STUDIES

: Binding energy of synthesized compounds with 8THH (Anti-Convulsant activity):

Ligand	Binding Affinity
MARP-1	-10.2
MARP-2	-10.9
MARP-3	-11.5
MARP-4	-
MARP-5	-10.4
MARP-6	-10.1
MARP-7	-10.2
MARP-8	-10.3
MARP-9	-10.7
MARP-10	-11.9
PHENYTOIN (Standard)	-8.6



MARP-3


6-(4-(((2-chlorophenyl)imino)methyl)phenoxy)-4-methyl-2H-chromen-2-one

Interactions
 van der Waals
 Pi-Cation
 Pi-Pi Stacked
 Pi-Pi T-shaped
 Alkyl
 Pi-Alkyl



Binding energy of synthesized compounds with 4CYG (Anti-Inflammatory activity):

Ligand	Binding Affinity
MARP-1	-11
MARP-2	-10.7
MARP-3	-10.9
MARP-4	-
MARP-5	-10.9
MARP-6	-10.8
MARP-7	-10.7
MARP-8	-11
MARP-9	-10.7
MARP-10	-10.7
INDOMETHACIN	-8.6



MARP-1

7-(4-(((4-chlorophenyl)imino)methyl)phenoxy)-4-methyl-2H-chromen-2-one


International Research Journal

IJNRD

Research Through Innovation

Binding energy of synthesized compounds with 3GNY(Gram positive) 1ZMH(Gram negative) (Anti-Microbial activity):

Ligand	Binding Affinity	
	GRAM POSITIVE	GRAM NEGATIVE
MARP-1	-6.9	-6.8
MARP-2	-6.8	-6.9
MARP-3	-6.9	-6.9
MARP-4	-	-
MARP-5	-6.6	-6.9
MARP-6	-6.6	-6.7
MARP-7	-6.5	-6.6
MARP-8	-6.9	-6.9
MARP-9	-6.8	-6.9
MARP-10	-7.4	-7.1
STANDARD DRUG	-4.2 (Penicillin)	-4.1 (Cephalosporin)



MARP-10

6-(4-(((4'-amino-[1,1'-biphenyl]-4-yl)imino)methyl)phenoxy)-4-methyl-2H-chromen-2-one

Interactions

- van der Waals
- Pi-Sulfur
- Pi-Pi Stacked
- Pi-Pi T-shaped
- Alkyl
- Pi-Alkyl



In-silico Toxicity studies of synthesized compounds

Compound code	Predicted LD50 (mg/kg)	Predicted Toxicity Class	Hepatotoxicity	Carcinogenicity	Immunotoxicity	Mutagenicity	Cytotoxicity
MARP-1	2850	5	Active	Active	Inactive	Inactive	Inactive
MARP-2	2850	5	Active	Active	Active	Inactive	Inactive
MARP-3	2850	5	Active	Active	Inactive	Inactive	Inactive
MARP-4	1190	4	Active	Inactive	Active	Inactive	Inactive
MARP-5	2850	5	Inactive	Active	Inactive	Inactive	Inactive
MARP-6	2000	4	Active	Inactive	Active	Active	Inactive
MARP-7	1500	4	Active	Active	Inactive	Inactive	Inactive
MARP-8	2850	5	Inactive	Active	Inactive	Inactive	Inactive
MARP-9	2000	4	Active	Active	Active	Active	Inactive
MARP-10	2000	4	Active	Active	Inactive	Active	Inactive

In-Silico Physicochemical studies obtained from Molinspiration

<i>Compound Code</i>	<i>miLogP</i>	<i>TPSA</i>	<i>ratoms</i>	<i>MW (g/mol)</i>	<i>nO</i>	<i>nOHN</i>	<i>nviolation</i>	<i>nrotb</i>	<i>Volume</i>
MARP-1	6.33	51.81	28	389.84	4	0	1	4	333.75
MARP-2	5.82	51.81	28	373.38	4	0	1	4	325.14
MARP-3	6.28	51.81	28	389.84	4	0	1	4	333.75
MARP-4	6.46	51.81	28	434.29	4	0	1	4	338.10
MARP-5	6.10	51.81	28	369.42	4	0	1	4	336.77
MARP-6	6.10	51.81	28	369.42	4	0	1	4	336.77
MARP-7	5.39	72.04	28	371.39	5	1	1	4	323.23
MARP-8	6.08	51.81	28	369.42	4	0	1	4	336.77
MARP-9	6.05	51.81	28	369.42	4	0	1	4	336.77
MARP-10	6.52	77.83	34	402.91	5	2	1	5	402.91



Table 35: In-silico ADME properties obtained from SwissADME

Compound code	MAR P-1	MAR P-2	MAR P-3	MAR P-4	MAR P-5	MAR P-6	MAR P-7	MAR P-8	MAR P-9	MAR P-10
Num. heavy atoms	28	28	28	28	28	30	28	28	30	34
Num. Arom. Heavy atoms	22	22	22	22	22	22	22	22	22	28
Num. Rotatable bonds	4	4	4	4	4	6	4	4	5	5
Num. H-bond acceptors	4	4	4	4	4	5	5	4	6	4
Num. of H-bond donors	0	0	0	0	0	0	1	0	0	1
Molar refractivity	112.67	112.67	112.67	112.67	112.63	116.48	109.68	112.67	116.48	137.50
Total Polar Surface Area(Å²)	51.80	51.80	51.80	51.80	51.80	97.62	72.03	51.80	97.62	77.82
Log Po/w (ilop)	4.04	4.04	4.14	4.04	3.99	3.58	3.39	3.86	3.50	4.11
Water solubility	Mode rately solubl e	Mode rately solubl e	Mode rately solubl e	Poorl ysolu ble	Mode rately solubl e	Mode rately solubl e	Mode rately solubl e	Mode rately solubl e	Mode rately solubl e	Poorly soluble
GI absorp tion	High	High	high	High	High	High	High	High	High	Low







BBB permeant	No	No	No	No	No	No	No	No	No	No
Drug likeness (violation)	Yes; (1)	Yes; (0)	Yes; (1)	Yes; (1)	Yes; (0)	Yes; (0)	Yes; (0)	Yes; (0)	Yes; (0)	Yes; (1)
Lead likeness (violation)	No; 2 violations: MW>350, XLO GP3 >3.5	No; 2 violations: MW>350, XLO GP3 >3.5	No; 2 violations: MW>350, XLO GP3 >3.5	No; 2 violations: MW>350, XLO GP3 >3.5	No; 2 violations: MW>350, XLO GP3 >3.5	No; 2 violations: MW>350, XLO GP3 >3.5	No; 2 violations: MW>350, XLO GP3 >3.5	No; 2 violations: MW>350, XLO GP3 >3.5	No; 2 violations: MW>350, XLO GP3 >3.5	No; 2 violations: MW>350, XLOG P3>3.5

Biological activities

Anti-convulsant activity 4-methyl-7-(4-((p-tolylimino)methyl)phenoxy)-2H-chromen-2-one against MES – induced convulsion.

Sl No	Groups	Body weight	Dose and Route	Flexion (sec)	Extensor (sec)	Clonus (sec)	Stupor (sec)	Recovery (%)
1	Control	31.3±0.33	0.5% (CMC) (i.p)	3.33±0.07	15.7±0.539	7.31±0.498	52.6±2.301	0
2	Standard	27.5±1.565	25mg Phenytoin (i.p)	2.03±0.374	Absent	2.09±0.137	7.68±0.372	100%
3	MARP-3	28.1±1.264	50mg MARP-3 (i.p)	1.8±0.324	6.7±0.303	4.21±0.150	16.49±0.58	66.6%
4	MARP-9	26±1.264	50mg MARP-9	2.32±0.127	9.34±0.227	3.72±0.277	20.7±0.580	33.3%

			(i.p)					
5	MARP -10	27±1.238	50mg MARP-10 (i.p)	2.11±0.105	7.13±0.376	4.45±0.194	21.8±0.461	100%





: *In-vitro* antioxidant activity of synthesized Coumarin substituted compounds.

SI. No	Compound code	% inhibition					
		50µg	100 µg	200 µg	400 µg	600 µg	IC ₅₀
1	MARP-1	39.7	60.7	67.7	83.1	90	162.9
2	MARP-2	15.9	32.57	45.5	66.3	81.4	336.2
3	MARP-3	22.5	43	56.7	70.2	82.5	50.45
4	MARP-4	34.7	56.3	62.2	78.4	85.2	218
5	MARP-5	25.64	39.6	50.3	75.7	83.9	279
6	MARP-6	20.6	35.8	44.6	60.7	77.8	337
7	MARP-7	21.1	41.9	48.1	68.9	83.8	303.4
8	MARP-8	35.8	57	63.4	81.1	88.2	198.7
9	MARP-9	33.3	46.9	57.1	77.5	84.2	320.4
10	MARP-10	27.9	33.1	43.3	59.1	75.9	302.9
11	Ascorbic acid	49.3	62.5	79.1	85.5	97.8	58.7





Fig31: Graphical representation of antioxidant activity by DPPH method



DPPH Experimentation

: *In-vitro* anti-inflammatory activity of synthesized coumarin derivatives.

SI. No	Compound code	% inhibition				
		50µg	100µg	200µg	600µg	IC ₅₀
1	MARP-1	8	27	57	78	258
2	MARP-2	7	12	26	34	607.4
3	MARP-3	5	10	19	31	655.76
4	MARP-4	8	51	84	78	258.10
5	MARP-5	8	15	38	52	384.09
6	MARP-6	6	10	20	48	411.52
7	MARP-7	6	12	31	41	490
8	MARP-8	16	33	62	69	273.5
9	MARP-9	3	12	33	51	392.7
10	MARP-10	5	24	42	89	236.7
11	Indomethacin	10	14	32	51	391.4



Acknowledgements

A heartfelt thanks...

With his holiness blessings, I express my sincere gratitude for the unwavering support, guidance, and encouragement you have provided throughout my research journey. Your contributions have played an indispensable role in shaping the success of my work, and I am truly grateful for each one of you

*My sincere thanks to my respected guide **Mr. Rakesh Panda**, Associate Professor, Department of Pharmaceutical Chemistry who was always the guiding light in my academic pursuits. Her extensive knowledge, profound guidance, and constant encouragement have been invaluable.*

*To **Dr. Kalpana Davi**, my esteemed professors, department of pharmaceutical chemistry I am indebted for their unyielding support and insightful feedback. Their dedication to nurturing student's growth has left an indelible mark on my academic journey.*

*A special thanks to my friends **Ayesha Nida, Salma, Deb Prasad Ghosh, Manjunath C** for lending a helping hand whenever needed it.*

*Lastly, I am really grateful to **Shaiq, Shafi, Rajeshwari, Nazeer and Ratna**, laboratory attendants for their assistant and constant support throughout my research.*

International Research Journal
IJNRD
Research Through Innovation

BIBLIOGRAPHY

1. Sharma M, Vyas VK, Bhatt S, Ghate MD. Therapeutic potential of 4-substituted coumarins: A conspectus. *Eur J Med Chem Rep.* 2022;6:100086.
2. Zhou R, Yu YH, Kim H, Ha HH. Synthesis of coumarin derivatives and investigation of their inhibitory effects on lung cancer cell motility. *Sci Rep* 2022;12(1):21635.
3. Ivanov IC, Angelova VT, Vassilev N, Tiritiris I, Iliev B. Synthesis of 4-aminocoumarin derivatives with N-substitutents containing hydroxy or amino groups. *Z Naturforsch B chem scp.* 2013; 68(9):1031-40.
4. Lippe D S, Elghawy O, Adam M. Zucker , Evan S. K. Yanagawa, Mathews E *et.al* Synthesis of 7-aminocoumarins from 7-hydroxycoumarins via amide smiles rearrangement. *ACS omega.* 2022;7(39):35269-79.
5. Czerpak R, Skalska S. Effect of selected synthetic growth regulators on *Pseudomonas aeruginosa* growth in liquid culture. *Med Dosw Mikrobiol.* 1982;34(1-2):37-50.
6. Jurd L, Corse J, King Jr AD, Bayne H, Mihara K. Antimicrobial properties of 6, 7-dihydroxy-, 7,8-dihydroxy-, 6-hydroxy and 8-hydroxycoumarins. *Phytochem.* 1971;10(12):2971-4.
8. Al Ansary SL, Aly EI, Halem MA. New coumarian derivatives as antibacterial agents. *Egypt J Pharm Sci.* 1992;33(1-2):379-90.

